NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT00436618 2019-10-22Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous TreatmentMayo ClinicPhase 2 Completed277 enrolled 11 charts
NCT00474929 2019-08-20Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaMayo ClinicPhase 1/2 Completed103 enrolled 12 charts
NCT00967044 2015-02-26Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory LymphomaM.D. Anderson Cancer CenterPhase 1/2 Completed31 enrolled 6 charts
NCT00962507 2013-02-15Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaCity of Hope Medical CenterPhase 1 Completed11 enrolled